Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Celiberto, Larissa Sbaglia ^a   Bedani, Raquel ^b   Dejani, Naiara Naiana ^a,b   De Medeiros, Alexandra Ivo ^a   Zuanon, José Antonio Sampaio ^a   Spolidorio, Luis Carlos ^a   Adorno, Maria Angela Tallarico ^b   Varesche, Maria Bernadete Amâncio ^b   Galvão, Fábio Carrilho ^a   Valentini, Sandro Roberto ^a   De Valdez, Graciela Font ^c   Rossi, Elizeu Antonio ^a   Cavallini, Daniela Cardoso Umbelino ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; NITRITE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; VOLATILE FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL SURVIVAL; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; BIOCHEMICAL ANALYSIS; COLITIS; COLON; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYPT CELL; DISEASE ACTIVITY; DISEASE SEVERITY; ENTEROCOCCUS FAECIUM; FECES MICROFLORA; GASTROINTESTINAL TRACT; HISTOPATHOLOGY; INFLAMMATION; INTESTINE ULCER; LACTOBACILLUS; MALE; MOLECULAR ANALYSIS; NONHUMAN; RAT; THERAPY EFFECT; ANIMAL; BEVERAGE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; FECES; INTESTINE; MICROBIOLOGY; TREATMENT OUTCOME;

ANIMALS; BEVERAGES; BIFIDOBACTERIUM LONGUM; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENTEROCOCCUS FAECIUM; FATTY ACIDS, VOLATILE; FECES; INTESTINES; PROBIOTICS; RATS; TREATMENT OUTCOME;

EID: 85018577363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175935     Document Type: Article

References (124)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12 Suppl 1(January):S3-9.
2. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis [Internet]. 2012; 18(11):2034-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22294550 https:// doi.org/10.1002/ibd.22901 PMID: 22294550
3. Celiberto LS, Bedani R, Rossi EA, Cavallini DCU. Probiotics: The Scientific Evidence in the Context of Inflammatory Bowel Disease. Crit Rev Food Sci Nutr [Internet]. 2015;0. Available from: http://www. ncbi.nlm.nih.gov/pubmed/25996176
4. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol [Internet]. 2010; 7(3):163-73. Available from: https://apps. webofknowledge.com/full-record.do?product=UA&search-mode=GeneralSearch&qid=1&SID= 2DL6fR8Dr3vnKjvGgpo&page=1&doc=1&cacheurlFromRightClick=no https://doi.org/10.1038/ nrgastro.2010.4 PMID: 20101257
5. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Vol. 17, Inflammatory Bowel Diseases. 2011. p. 362-81. https://doi.org/10.1002/ibd.21403 PMID: 20725949
6. Arab HH, Salama SA, Eid AH, Omar HA, Arafa ESA, Maghrabi IA. Camel's milk ameliorates TNBSinduced colitis in rats via downregulation of inflammatory cytokines and oxidative stress. Food Chem Toxicol. 2014; 69:294-302. https://doi.org/10.1016/j.fct.2014.04.032 PMID: 24788059
7. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Vol. 115, Gastroenterology. 1998. p. 182-205. PMID: 9649475
8. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol [Internet]. 2014; 14(5):329-42. Available from: https://doi.org/10.1038/nri3661\nhttp://www.nature.com/nri/journal/v14/n5/pdf/ nri3661.pdf https://doi.org/10.1038/nri3661 PMID: 24751956
9. Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol [Internet]. 1995; 100(3):452-6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1534463&tool= pmcentrez&rendertype=abstract PMID: 7774055
10. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol [Internet]. 2002; 20:495-549. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 11861611 https://doi.org/10.1146/annurev.immunol.20.100301.064816 PMID: 11861611
11. Feagins L. Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis [Internet]. 2010; 16(11):1963-8. Available from: http://www.ncbi.nlm. nih.gov/pubmed/20848467\nhttp://content.wkhealth.com/linkback/openurl?sid=WKPTLP: landingpage&an=00054725-201011000-00023 https://doi.org/10.1002/ibd.21281 PMID: 20848467
12. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol [Internet]. 2002; 169(4):2204-9. Available from: http://www.jimmunol.org/content/169/4/2204.full PMID: 12165551
13. Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol. 2006; 101(4):793-7. https://doi.org/10.1111/j.1572-0241.2005.00356.x PMID: 16635225
14. Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, et al. Interferon--1a for the treatment of steroid-refractory ulcerative colitis: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2005; 3(6):581-6. PMID: 15952100
15. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology [Internet]. 1995; 109(1):129-35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7797011 \nhttp://ac.els-cdn.com/0016508595902775/1-s2.0-0016508595902775-main.pdf?-tid=4bb75ede- 76f0-11e3-9756-00000aacb35d&acdnat=1389026198-8cac7c3752418e248338b851b8058bcf PMID: 7797011
16. Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potention new probiotic, alleviates symtoms of colitis unduced by dextran sulphate sodium (DSS) in rats. Int J Food Microbiol. 2007; 114:267-274. https://doi.org/10.1016/j.ijfoodmicro.2006.09.018 PMID: 17150273
17. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol. 2008; 23(12):1834-9. https://doi.org/10.1111/j.1440-1746.2008. 05723.x PMID: 19120873
18. Osman N, Adawi D, Molin G, Ahrne S, Berggren A, Jeppsson B. Bifidobacterium infantis strains with and without a combination of oligofructose and inulin attenuate inflammation in DSS-induced colitis in rats. BMC Gastroenterol. 2006; 6:31. https://doi.org/10.1186/1471-230X-6-31 PMID: 17069659
19. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis. 2011; 17(1):289-97. https://doi.org/10.1002/ibd.21366 PMID: 20564535
20. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10(3):286-99. PMID: 15290926
21. O'Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. ScientificWorld- Journal. 2007; 7:31-46. https://doi.org/10.1100/tsw.2007.26 PMID: 17221140
22. Howarth GS. Inflammatory bowel disease, a dysregulated host-microbiota interaction: are probiotics a new therapeutic option? J Gastroenterol Hepatol. 2008; 23:1775-1784.
23. Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: Relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007; 150(3):531-8. https://doi.org/10.1111/j.1365-2249.2007.03522.x PMID: 17956582
24. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004; 10:1521-5. https://doi.org/10.3748/wjg. v10.i10.1521 PMID: 15133865
25. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL, et al. Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis. 2006; 21(8):737-46. https://doi.org/10.1007/s00384-005-0773-y PMID: 16052308
26. Girishkumar B, Henry DE, Srinivasan K, Prapulla SG. Beneficial effect of a probiotic Lactobacillus fermentum CFR 2195 in trinitrobenzenesulfonate induced colitis in rat. Ann Food Sci and Techn. 2012; 13(2):231-239.
27. Ocon B, Anzola A, Ortega-Gonzalez M, Zarzuelo A, Suarez MD, Sanchez De Medina F, et al. Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis. Eur J Nutr. 2013; 52(2):457-66. https://doi.org/10.1007/s00394-012-0347-z PMID: 22941198
28. Cavallini DCU, Suziki JY, Abdalla DSP, Vendramini RC, Pauly-Silveira ND, Roselino MN. Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model. Lip Health Dis. 2011; 10:126.
29. Sivieri K, Spinardi-Barbisan ALT, Barbisan LF, Bedani R, Pauly ND, Carlos IZ, et al. Probiotic Enterococcus faecium CRL 183 inhibit chemically induced colon cancer in male wistar rats. Eur Food Res Technol. 2008; 228(2):231-7.
30. Vendramini AP. Efeito da ingestão de um produto de soja fermentado com Enterococcus faecium e Lactobacillus helveticus na produção de citocinas, óxido nítrico e peróxido de hidrogênio. M.Sc. Thesis, Faculdade de Ciências Farmacêuticas de Araraquara/UNESP, 2002. Available: http://www2.fcfar. unesp.br/#!/pos-graduacao/biociencias-e-biotecnologias-aplicadas-a-farmacia/dissertacoes-teses/ 2002/
31. Rossi EA, Reddy KV, Silva RSSF. Formulation of soy-whey yogurt, using response surface methodology. Arq Biol Tecnol. 1984; 27:387-390.
32. Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993; 38(9):1722-34. PMID: 8359087
33. Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol [Internet]. 1995; 268(4):G622-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 7733288.
34. Camuesco D, Peran L, Comalada M, Nieto A, Di Stasi LC, Rodriguez-Cabezas ME, Concha A, Zarzuelo A, Galvez J. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis. 2005; 11:265-271. PMID: 15735433
35. Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis. 2000; 32(1):81-5. PMID: 10716083
36. Yoshiota H, Iseki K, Fujita K. Development and difference of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics. 1983; 72:317-321. PMID: 6412205
37. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol. 2001; 152(8):735-41. PMID: 11686387
38. Marzotto M, Maffeis C, Paternoster T, Ferrario R, Rizzotti L, Pellegrino M, et al. Lactobacillus paracasei A survives gastrointestinal passage and affects the fecal microbiota of healthy infants. Res Microbiol. 2006; 157(9):857-66. https://doi.org/10.1016/j.resmic.2006.06.007 PMID: 16934438
39. Livingston SJ, Kominos SD, Yee RB. New medium for selection and presumptive identification of the Bacteroides fragilis group. J Clin Microbiol. 1978; 7(5):448-53. PMID: 659574
40. Munoa FJ, Pares R. Selective medium for isolation and enumeration of Bifidobacterium spp. Appl Environ Microbiol. 1988; 54:1715-1718. PMID: 3415235
41. Lane TE, Wu-Hsieh BA, Howard DH. Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state. Infec Immun. 1996; 61(4):1468-73.
42. De Wiele T Van, Boon N, Possemiers S, Jacobs H, Verstraete W. Prebiotic effects of chicory inulin in the simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol. 2004; 51(1):143-53. https://doi.org/10.1016/j.femsec.2004.07.014 PMID: 16329863
43. Adorno MAT, Hirasawa JS, Varesche MBA. Development and Validation of Two Methods to Quantify Volatile Ac- ids (C2-C6) by GC/FID: Headspace (Automatic and Manual) and Liquid-Liquid Extraction (LLE). Am J Anal Chem. 2014; 5:406-414.
44. Bedani R, Pauly-Silveira ND, Cano VSP, Valentini SR, de Valdez GF, Rossi EA. Effect of ingestion of soy yogurt on intestinal parameters of rats fed on a beef-based animal diet. Brazilian J Microbiol. 2011; 42(3):1238-47.
45. Sivieri K, Cano VPS, Valentini SR, Rossi EA. Gastrointestinal survival of Enterococcus faecium CRL 183 in rats. Le Lait. 2007; 87:59-69.
46. Langa S, Fernandez A, Martin R, Reviriego C, Marin ML, Fernandez L, et al. Differentiation of Enterococcus faecium from Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus strains by PCR and dot-blot hybridisation. In: International Journal of Food Microbiology. 2003. p. 197-200.
47. Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA gene-targeted species-specific primers. Appl Environ Microbiol. 1999; 65:4512-1999.
48. Shiguemoto GE, Rossi EA, Baldissera V, Gouveia CH, de Valdez Vargas GMF, de Andrade Perez SE. Isoflavone-supplemented soy yoghurt associated with resistive physical exercise increase bone mineral density of ovariectomized rats. Maturitas. 2007; 57(3):261-70. https://doi.org/10.1016/j. maturitas.2007.01.011 PMID: 17368767
49. Redondo NC. Avaliação in vitro de características probióticas do Enterococcus faecium CRL 183 e do Lactobacillus helveticus ssp. jugurti 416. M.Sc. Thesis, Faculdade de Ciências Farmacêuticas de Araraquara/ UNESP, 2008. Available: http://www2.fcfar.unesp.br/Home/Pos-graduacao/ AlimentoseNutricao/nadia-redondo-completo.pdf
50. Kinouchi FL, Maia DCG, de Abreu Ribeiro LC, Placeres MCP, de Valdez GF, Colombo LL, et al. A soy-based product fermented by Enterococcus faecium and Lactobacillus helveticus inhibits the development of murine breast adenocarcinoma. Food Chem Toxicol. 2012; 50(11):4144-8. https:// doi.org/10.1016/j.fct.2012.08.038 PMID: 22954488
51. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Alimentos com alegaçies de propriedades funcionais e ou de saúde, novos alimentos/ingredientes, substâncias bioativas e probió ticos. 2008 Available: http://portal.anvisa.gov.br/wps/content/Anvisa+Portal/Anvisa/Inicio/Alimentos/Assuntos+de +Interesse/Alimentos+Com+Alegacoes+de+Propriedades+Funcionais+e+ou+de+Saude/Avaliacao +de+seguranca+e+comprovacao+de+eficacia
52. Bertazzoni E, Donelli G, Midtvet T, Nicoli J, Sanz Y. Probiotics and clinical effects: is the number what counts? J Chemother. 2013; 25(4):193-212. https://doi.org/10.1179/1973947813Y.0000000078 PMID: 23906073
53. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012; 2012:1-13.
54. Malago JJ, Nondoli H. Sodium arsenite reduces severity of dextran sulfate sodium-induced ulcerative colitis in rats. J Zhejiang Univ Sci B [Internet]. 2008; 9(4):341-50. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=2276679&tool=pmcentrez&rendertype=abstract https://doi.org/10.1631/jzus.B0720198 PMID: 18381811
55. Ozaki K, Makino H, Aoki M, Miyake T, Yasumasa N, Osako MK, Nakagami H, Rakugi H, Morishita R. Therapeutic effect of ribbon-type nuclear factor-κb decoy oligonucleotides in a rat model of inflammatory bowel disease. Curr Gene Ther. 2012; 12(6):484-492. PMID: 23061565
56. Jo SG, Noh EJ, Lee JY, Kim G, Choi JH, Lee ME, Song JH, Chang JY, Park JH. Lactobacillus curvatus WiKim38 isolated from kimchi induces IL-10 production in dendritic cells and alleviates DSS-induced colitis in mice. J Microbiol. 2016; 54(7):503-9 https://doi.org/10.1007/s12275-016-6160-2 PMID: 27350616
57. Ahl D, Liu H, Schreiber O, Roos S, Phillipson M, Holm L. Lactobacillus reuteri increases mucus thickness and ameliorates dextran sulphate sodium-induced colitis in mice. Acta Physiol (Oxf). 2016; 217 (4):300-10.
58. Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF, Granger DN. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004; 49(4):556-64. PMID: 15185857
59. Zhou FX, Chen L, Liu XW, Ouyang CH, Wu XP, Wang XH, et al. Lactobacillus crispatus M206119 exacerbates murine DSScolitis by interfering with inflammatory responses. World J Gastroenterol. 2012; 18(19):2344-56. https://doi.org/10.3748/wjg.v18.i19.2344 PMID: 22654425
60. García-Lafuente A, Guillamón E, Villares A, Rostagno MA, Martínez JA. Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease. Vol. 58, Inflammation Research. 2009; 537-52. https://doi.org/10.1007/s00011-009-0037-3 PMID: 19381780
61. Moussa L, Bezirard V, Salvador-Cartier C, Bacquie V, Lencina C, Leveque M, et al. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease. Plos One. 2012; 7(11):e49547. https://doi.org/10.1371/journal.pone. 0049547 PMID: 23166707
62. Panneerselvam S, Packirisamy RM, Bobby Z, Sridhar MG. Protective Effect of Soy Isoflavones (from Glycine max) on Adipose Tissue Oxidative Stress and Inflammatory Response in an Experimental Model of Post-menopausal Obesity: The Molecular Mechanisms. Biochem Anal Biochem 2016, 5:2.
63. Yu J, Bi X, Yu B, Chen D. Isoflavones: anti-inflammatory benefit and possible caveats. Nutrientes. 2016; 10(8):6.
64. Griffiths K, Aggarwal BB, Singh RB, Buttar HS, Wilson D, De Meester F. Food antioxidants and their anti-inflammatory properties: a potential role in cardiovascular diseases and cancer prevention. Diseases 2016, 4(3), 28.
65. Jiang H, Przybyszewski J, Mitra D, Becker C, Brehm-stecher B, Tentinger A, et al. Soy Protein Diet, but Not Lactobacillus rhamnosus GG, Decreases Mucin-1, Trefoil Factor-3, and Tumor Necrosis Factor- a in Colon of Dextran Sodium Sulfate-Treated C57BL/6 Mice. J Nutr [Internet]. 2011; 141(7):1239-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21593350 https://doi.org/10.3945/jn.110. 137414 PMID: 21593350
66. Travis SPL, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al. European evidence- based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008; 2(1):24-62.
67. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-asa) in treatment of inflammatory bowel disease: a systemic review. Dig Dis Sci. 2002; 47(3):471-488. PMID: 11911332
68. Mahida YR, Lamming CE, Gallagher A, Hawthorne B, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991; 32(1):50-4. PMID: 1846838
69. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. https://doi.org/10. 1056/NEJMra020831 PMID: 12167685
70. Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, et al. Reduced diversity and imbalace of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci. 2012; 57(11):2955-2964. https:// doi.org/10.1007/s10620-012-2236-y PMID: 22623042
71. Ettreiki C, Gadonna-Widehem P, Mangin I, Coëffier M, Delayre-Orthez C, Anton PM. Juvenile ferric iron prevents microbiota dysbiosis and colitis in adult rodents. World J Gastroenterol. 2012; 18 (21):2619-29. https://doi.org/10.3748/wjg.v18.i21.2619 PMID: 22690070
72. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003; 52:237-42. PMID: 12524406
73. Bedani R, Rossi EA, Saad SMI. Impact of inulin and okara on Lactobacillus acidophilus La-5 and Bifidobacterium animalis Bb-12 viability in a fermented soy product and probiotic survival under in vitro simulated gastrointestinal conditions. Food Microbiol. 2013; 34:382-389. https://doi.org/10.1016/j.fm. 2013.01.012 PMID: 23541206
74. Franz CMAP, Huch M, Abriouel H, Holzapfel W, Gálvez A. Enterococci as probiotics and their implications in food safety. Vol. 151, International Journal of Food Microbiology. 2011. p. 125-40. https://doi. org/10.1016/j.ijfoodmicro.2011.08.014 PMID: 21962867
75. Bedani R, Pauly-Silveira ND, Roselino MN, Valdez GF., Rossi EA. Effect of fermented soy product on the fecal microbiota of rats fed on a beef-based animal diet. Food Agric. 2010; 90:233-238.
76. Bourlioux P, Koletzco B, Guarne F, Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium The Intelligent Intestine'., held in Paris, 14 June 2002. Am J Clin Nutr. 2003; 78:675-678. PMID: 14522724
77. Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur J Pharma Sci. 2002; 15:1-9.
78. Ventura M, O'Flaherty S, Claesson MJ, Turroni F, Klaenhammer TR, van Sinderen D, et al. Genomescale analyses of health-promoting bacteria: probiogenomics. Nat Rev Microbiol [Internet]. 2009; 7 (1):61-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19029955 https://doi.org/10.1038/ nrmicro2047 PMID: 19029955
79. Bullock NR, Booth JCL, Gibson GR. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol. 2004; 5(2):59-64. PMID: 15460067
80. Wine E, Gareau MG, Johnson-Henry K, Sherman PM. Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells. FEMS Microbiol Lett. 2009; 300(1):146-52. https://doi.org/10.1111/j.1574-6968.2009.01781.x PMID: 19765084
81. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol [Internet]. 2013; 13(11):790-801. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 24096337 https://doi.org/10.1038/nri3535 PMID: 24096337
82. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11 (5):481-7. PMID: 15867588
83. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011; 105(5):755-64. https://doi.org/10.1017/ S0007114510004319 PMID: 20974015
84. Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Vol. 24, Brain, Behavior, and Immunity. 2010. p. 9-16. https://doi.org/10.1016/j.bbi.2009.05.058 PMID: 19481599
85. Ramiah K, van Reenen CA, Dicks LMT. Surface-bound proteins of Lactobacillus plantarum 423 that contribute to adhesion of Caco-2 cells and their role in competitive exclusion and displacement of Clostridium sporogenes and Enterococcus faecalis. Res Microbiol. 2008; 159(6):470-5. https://doi. org/10.1016/j.resmic.2008.06.002 PMID: 18619532
86. Yan F, POlk DB. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes. 2012; 3:25-28. https://doi.org/10.4161/gmic.19245 PMID: 22356855
87. Montesi A, Garca-Albiach R, Pozuelo MJ, Pintado C, Goi I, Rotger R. Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics or probiotics. Int J Food Microbiol. 2005; 98(3):281-9. https://doi.org/10.1016/j.ijfoodmicro.2004.06.005 PMID: 15698689
88. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet [Internet]. 2003; 360(1):512-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12583961\nhttp://www.ncbi.nlm.nih.gov/ pubmed/12781578
89. Sokol H, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol. 2006; 44(9):3172-7. https://doi.org/10.1128/JCM.02600-05 PMID: 16954244
90. Lam VY, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012; 26(4):1727-1735. https://doi.org/10.1096/fj. 11-197921 PMID: 22247331
91. Naruszewicz M, Johansson M-L, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr [Internet]. 2002; 76(6):1249-55. Available from: http://ajcn.nutrition.org/content/76/6/1249.long PMID: 12450890
92. Kringston DGI, Vantassel-Rlandwilkins TD. The fecapentenes, potent mutagens from human feces. Chem Res Toxicol. 1990; 3:391-400. PMID: 2133089
93. Krzyzanowsky F, Avila-Campos MJ. Detection of non-enterotoxigenic and enterotoxigenic Bacteroides fragilis in stool samples from children in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2003; 45(4):225-7. PMID: 14502352
94. Sheehan D, Moran C, Shanahan F. The Microbiota in Inflammatory Bowel Disease. J Gastroenterol. 2015; 50(5):495-507. https://doi.org/10.1007/s00535-015-1064-1 PMID: 25808229
95. Chu H, Khosravi A, Kusumawardhani IP, Kwon AH, Vanconcelos AC, Cunha LD, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016; 352:1116-1120. https://doi.org/10.1126/science.aad9948 PMID: 27230380
96. Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Dietinduced extinctions in the gut microbiota compound over generations. Nature. 2016; 529:212-215. https://doi.org/10.1038/nature16504 PMID: 26762459
97. Ubeda C, Bucci V, Cavallero S, Djukovic A, Toussaint NC, Equinda M. Intestinal Microbiota Containing Barnesiella Species Cures Vancomycin-Resistant Enterococcus faecium Colonization. Infect. Immun. 2013; 81(3):965-973. https://doi.org/10.1128/IAI.01197-12 PMID: 23319552
98. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998; 22(4):382-9. PMID: 9523521
99. Bento AF, Leite DFP, Marcon R, Claudino RF, Dutra RC, Cola M, et al. Evaluation of chemical mediators and cellular response during acute and chronic gut inflammatory response induced by dextran sodium sulfate in mice. Biochem Pharmacol. 2012; 84:1459-1469. https://doi.org/10.1016/j.bcp.2012. 09.007 PMID: 23000912
100. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G1328-G1338. https://doi.org/10.1152/ajpgi.00467. 2004 PMID: 15637179
101. Dieleman LA, Palmen MJHJ, Akol H, Bloemena E, Pena AS, Meuwissen SGM, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998; 114:385-391. https://doi.org/10.1046/j.1365-2249.1998.00728.x PMID: 9844047
102. Alex P, Zachos NC, Nguyen T, Gonzalez L, Chen T, Conklin LS, Centola M, Li X. Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-induced Colitis. Inflamm Bowel Dis 2009; 15:341-352. https://doi.org/10.1002/ibd.20753 PMID: 18942757
103. Jurjus AR, Khoury NN, Reimund J-M. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004; 50(2):81-92. https://doi.org/10.1016/j.vascn.2003.12.002 PMID: 15385082
104. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Vol. 113, Immunology. 2004. p. 427-37. https://doi.org/10.1111/j.1365-2567. 2004.01984.x PMID: 15554920
105. Aiko S, Grisham MB. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology. 1995; 109(1):142-50. PMID: 7797013
106. Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol. 1995; 268(4 Pt 1):G673-84.
107. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut. 1995; 36:718-23. PMID: 7541008
108. Vinolo MAR. Efeito dos ácidos graxos de cadeia curta sobre neutró filos. Ph.D Thesis, Universidade de São Paulo-USP, 2010. Available: http://www.teses.usp.br/teses/disponiveis/42/42137/tde- 10012011-152253/pt-br.php
109. Hooper L V, Midtvedt T, Gordon JI. How Host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr [Internet]. 2002; 22(1):283-307. Available from: http://www. annualreviews.org/doi/abs/10.1146/annurev.nutr.22.011602.092259
110. Ranganna K, Yousefipour Z, Yatsu FM, Milton SG, Hayes BE. Gene expression profile of butyrateinhibited vascular smooth muscle cell proliferation. Mol Cell Biochem [Internet]. 2003; 254(1-2):21-36. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=14674679 PMID: 14674679
111. Weber TE, Kerr BJ. Butyrate differentially regulates cytokines and proliferation in porcine peripheral blood mononuclear cells. Vet Immunol Immunopathol. 2006; 113(1-2):139-47. https://doi.org/10. 1016/j.vetimm.2006.04.006 PMID: 16725211
112. Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. 1998; 12(6):499-507. PMID: 9678808
113. Wolever TM, Schrade KB, Vogt JA, Tsihilias EB, MCburney MI. Do colonic short chain fatty acids contribute to the long term adaptation of blood lipids in subjects with type 2 diabetes consuming a high fiber diet? Am J Clin Nutr. 2002; 75(6):1023-1030. PMID: 12036809
114. Segain J, Blé tière DR De, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NF B inhibition: implications for Crohn's disease. Gut [Internet]. 2000; 47 (Cd):397-403. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 1728045&tool=pmcentrez&rendertype=abstract https://doi.org/10.1136/gut.47.3.397 PMID: 10940278
115. Nassri CGG, Nassri AB, Favero E, Rotta CM, Martinez CAR, Margarido NF. Influência da irrigação de soluçies nutricionais no colo excluso de trânsito intestinal. estudo experimental em ratos. Rev Bra Coloproctol. 2008; 28(3):306-314.
116. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chainfatty acid irrigation. N Engl J Med [Internet]. 1989; 320(1):23-8. Available from: http://www.ncbi.nlm. nih.gov/pubmed/2909876 https://doi.org/10.1056/NEJM198901053200105 PMID: 2909876
117. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001; 81(3):1031-64. PMID: 11427691
118. Morampudi V, Dalwadi U, Bhinder G, Sham HP, Gill SK, Chan J, et al. The goblet cell-derived mediator RELM-b drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal Immunol. 2016; 9(5):1218-33. https://doi.org/10.1038/mi.2015.140 PMID: 26813339
119. Mater DDG, Bretigny L, Firmesse O, Flores MJ, Mogenet A, Bresson JL, et al. Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus survive gastrointestinal transit of healthy volunteers consuming yogurt. FEMS Microbiol Lett. 2005; 250(2):185-7. https://doi.org/10.1016/j.femsle. 2005.07.006 PMID: 16099606
120. Bedani R. Influência do consumo de "iogurte" de soja fermentado com Enterococcus faecium CRL183 na microbiota intestinal de animais e humanos. Ph.D Thesis, Faculdade de Ciências Farmacêuticas de Araraquara/UNESP, 2008. Available: http://www2.fcfar.unesp.br/Home/Pos-graduacao/ AlimentoseNutricao/raquel-bedani-completo.pdf
121. Touré R, Kheadr E, Lacroix C, Moroni O, Fliss I. Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. J Appl Microbiol. 2003; 95 (5):1058-69. PMID: 14633035
122. Sakata S, Kitahara M, Sakamoto M, Hayashi H, Fukuyama M, Benno Y. Unification of Bifidobacterium infantis and Bifidobacterium suis as Bifidobacterium longum. Int J Syst Evol Microbiol. 2002; 52:1945-1951. https://doi.org/10.1099/00207713-52-6-1945 PMID: 12508852
123. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate producing colon bacteria during growth on oligofructose. Appl Environ Microbiol. 2006 Dec; 72(12): 7835-7841. https://doi.org/10.1128/AEM.01296-06 PMID: 17056678
124. Rivière A; Selak M; Lantin D; Leroy F; De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front Microbiol. 2016; 7:979. https://doi.org/10.3389/fmicb.2016.00979 PMID: 27446020